Cargando…
EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients
Bladder cancer is a leading cause of morbidity and mortality worldwide. Currently, immunotherapy has become a worthwhile therapy for bladder cancer. Tumor mutation burden (TMB) has been regarded as the most prevalent biomarker to predict immunotherapy. Bladder cancer is reported to have the third hi...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041765/ https://www.ncbi.nlm.nih.gov/pubmed/32012118 http://dx.doi.org/10.18632/aging.102728 |